A proteomics-based approach [63] revealed and validated one hundred and twelve regulatory proteins differentially expressed with bortezomib resistance in MM, and many of them interacted with XPO1 [63] (CSE1, DYNLL1, HSPA14, NUP88, NUP50, RAD21, RCC2, RANBP2, SMC1A, and TPR). The gene discussed is XPO1; the disease is Miyoshi myopathy.